Olympia Biosciences™

UEMS Medical Specialties · MeSH-Tagged Dossiers · CDMO Science

Therapeutic R&D Intelligence Hub

66 formulation dossiers indexed across UEMS medical specialties and CDMO technology domains — each anchored in peer-reviewed evidence. Select your field below.

⌘K to search any dossier

Smart Search

Find any dossier in seconds

Search by molecule, axis, challenge, category, or MeSH topic.

Try: bioavailability, PCOS, GLP-1, endotoxin, stability.

66

Published Dossiers

11

UEMS Specialties

5

CDMO Technology Domains

125M+

Papers Indexed via Elicit

Newest Research

Latest Publications

Formulation dossiers published most recently, sorted by date.

Alphabetical Reference Index

Complete R&D Dossier Index

66 evidence-based formulation dossiers — click any title to access the full research article.

Evidence-Based Medicine

The Science of Formulation: Our Commitment to Evidence-Based Medicine

At Olympia Biosciences—a premier global Contract Development and Manufacturing Organization (CDMO) proudly rooted in Poland—we believe that world-class health solutions begin with uncompromising scientific rigor. As a dedicated, pure-play B2B partner, we do not own, market, or sell proprietary consumer brands. Our sole mission is to serve as the scientific and operational powerhouse behind the world's elite doctor-led brands and healthcare enterprises that demand the highest standards of quality, safety, and Evidence-Based Medicine (EBM).

Why We Publish Independent Scientific Literature

Behind every formulation we engineer stands a multidisciplinary team of medical doctors, biotechnologists, and research scientists. While we strictly adhere to global regulatory frameworks—routinely equipping our partners with comprehensive, EFSA-compliant claim declarations—we also recognize a fundamental reality of modern healthcare: the pace of clinical discovery frequently outstrips the speed of institutional updates.

We hold the utmost respect for global regulatory authorities, yet for our team, basic compliance is merely the baseline. We proactively analyze emerging clinical and scientific data because we must be absolutely certain that every formulation we develop is fundamentally safe, highly bioavailable, and unequivocally effective within its targeted scope.

The independent medical and scientific reviews published on our platform are general overviews, not tied to any specific commercial product. They reflect our mandate to champion the science that drives the industry forward. By bridging the gap between cutting-edge academic research and commercial manufacturing, Olympia Biosciences empowers your brand to deliver market-leading products defined by genuine scientific integrity.

Shape Our Research Agenda

Didn't find your research topic?

Tell us what formulation science challenge you're working on. We review every suggestion — if we develop the dossier, we'll notify you first. No cost. No commitment. Just science.

✓ Free ✓ Assessed by Olimpia Baranowska ✓ You'll be first to receive the dossier

Your data is used only to notify you when the dossier is published. No marketing emails.

Science Newsletter

New R&D Article Every Week

Get Olimpia's latest therapeutic research insights delivered straight to your inbox. B2B formulators & pharma scientists only.

No spam. Unsubscribe anytime. One email per week.

Our IP Pledge

We do not own consumer brands. We never compete with our clients.

Every formula engineered at Olympia Biosciences™ is built from scratch and transferred to you with full intellectual property ownership. Zero conflict of interest — guaranteed by ISO 27001 cybersecurity and ironclad NDAs.